Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Typical warning signs for sleep apnea

Typical warning signs for sleep apnea

New guidelines for pulmonary arterial hypertension caution the use of calcium channel blockers

New guidelines for pulmonary arterial hypertension caution the use of calcium channel blockers

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

Tommy G. Thompson has announced a new Medicare program that will save seniors and the disabled substantial money

Tommy G. Thompson has announced a new Medicare program that will save seniors and the disabled substantial money

Wyeth to appeal $1 billion awarded to the family of a woman who died after using fen-phen diet drug

Wyeth to appeal $1 billion awarded to the family of a woman who died after using fen-phen diet drug

Oral sildenafil improved exercise tolerance, cardiac output and quality of life in 22 patients with primary pulmonary hypertension

Oral sildenafil improved exercise tolerance, cardiac output and quality of life in 22 patients with primary pulmonary hypertension